Anchor Therapeutics Enters Into Collaborative Research Agreement With Kyowa Hakko Kirin for its Pepducin Technology
7/31/2012 9:51:28 AM
More...
|
Anchor Therapeutics Achieves Milestone in GPCR Collaboration
1/10/2011 11:45:58 AM
More...
|
Anchor Therapeutics Announces Collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., Potential $480 Million in Milestones
9/9/2010 6:33:31 AM
More...
|
Anchor Therapeutics Nabs $10M for New Class of Peptide Drugs Against Hard Targets
8/20/2010 6:58:03 AM
More...
|
Anchor Therapeutics Adds Global Experts to Board of Directors and Scientific Advisory Board
7/21/2010 12:41:38 PM
More...
|
Ascent Therapeutics Changes Name to Anchor Therapeutics
3/30/2010 8:51:30 AM
More...
|
Ascent Therapeutics Achieves Preclinical in vivo Proof-of-Principle with Novel Pepducin(TM) GPCR Modulator Platform and Strengthens Senior Management Team
9/11/2009 9:52:08 AM
More...
|
Ascent Therapeutics Appoints Industry Leaders to Senior Management Team
6/3/2009 8:54:11 AM
More...
|
Massachusetts Biotechnology Council, Inc. Release: 19 Biotech Companies Selected to Present at 10th Annual MassBio Investors Forum
12/2/2008 12:29:28 PM
More...
|
Ascent Therapeutics Debuts with the Appointment of CEO; $19 Million Series A
11/18/2008 8:28:28 AM
More...
|